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Edited by Michael R. BubbAbstract We investigated the eﬀects of advanced glycation end
products (AGE) which accumulate in articular cartilage with age
in human osteoarthritic chondrocytes. We found AGE-BSA sig-
niﬁcantly increased MMP-1, -3, and -13, and TNF-a in a dose-
dependent manner. AGE-BSA-stimulated JNK, p38, and ERK
and NF-jB activity. The stimulatory eﬀect of AGE-BSA on
MMP-1, -3, and -13 were reversed by treatment with speciﬁc
JNK, p38 inhibitors, suggesting JNK and p38 are involved in
AGE-BSA-induced MMPs and TNF-a. We also observed that
NF-jB is involved in AGE-BSA-induced TNF-a. Pretreatment
with soluble receptor for AGE (sRAGE) also reduced AGE-stim-
ulated MMPs and TNF-a, implicating the involvement of recep-
tor for AGE (RAGE). In conclusion, accumulation of AGE may
have a role in the development of osteoarthritis by increasing
MMP-1, -3, and -13, and TNF-a.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Aging has been considered one of the most important risk
factors for the development osteoarthritis (OA) [1], but the
precise contribution of aging largely remains unknown.
Advanced glycation end products (AGE), which are non-
enzymatic adducts of proteins, lipids, and nucleic acids, accu-
mulate in the body with advanced age [2,3]. Articular cartilage
is particularly sensitive to the accumulation of AGE because
the half-life of type II collagen is more than 100 years [4]. A
recent in vivo study demonstrated upregulated AGE levels in
the knee cartilage of beagle dogs increased susceptibility to
the development of OA [5]. Accumulation of AGE also in-Abbreviations: AGE, advanced glycation end products; TNF-a, tumor
necrosis factor a; MMP, matrix metalloproteinase; NF-jB, nuclear
factor-kappa B; OA, osteoarthritis
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doi:10.1016/j.febslet.2007.03.090creased tissue stiﬀness in articular cartilage [6,7] and rendered
articular cartilage tissue more brittle [8,9].
The receptor for AGE (RAGE) is expressed in articular
chondrocytes and synovial tissue macrophages of individuals
with rheumatoid arthritis (RA) [10,11]. Activation of RAGE
in individuals with OA was found to stimulate chondrocytes
and synoviocytes, resulting in increased production of matrix
metalloproteinase 1 (MMP-1) [12].
We hypothesized AGE may inﬂuence the catabolic process
in OA and tested the eﬀect of AGE on the production of
MMP-1, -3, and -13, and tumor necrosis factor a (TNF-a) in
OA chondrocytes.2. Materials and methods
2.1. Specimen selection and chondrocyte cultures
With institutional review board (IRB) approval, cartilage was iso-
lated from the knee joints of 28 OA patients aged 59–76 years (mean
age 68 years) who were undergoing knee replacement surgery at Asan
Medical Center, Seoul, Korea. All studies were carried out according
to the Declaration of Helsinki guidelines, and written informed con-
sent was obtained from each patient.
In brief, each cartilage was thinly sliced, minced, and incubated with
agitation for 14–18 h at 37 C in DMEM (Invitrogen, Carlsbad, CA)
containing 1 mg/ml collagenase (Gibco-BRL, San Diego, CA), 1%
antibiotic–antimycotic solution (Gibco-BRL), and 10% FBS. After
digestion, the chondrocytes were passed through a 70-lm cell strainer
(BD Biosciences, Franklin Lakes, NJ), washed with serum-free media,
counted, resuspended in culture media, and seeded at 5 · 106 cells in
10-cm culture plates in DMEM supplemented with 10% FBS, 1%
L-glutamine, 1% fungizone (Gibco-BRL), and penicillin/streptomycin
(150 U/ml and 50 mg/ml, respectively). All experiments were per-
formed within 5 days of the primary culture to avoid dediﬀerentiation
of OA chondrocytes.
2.2. Immunohistochemistry
Chondrocytes (5 · 106) were placed on Falcon culture slides (BD
Biosciences) in 10-cm culture plates and cultured for 48 h. The cells
were ﬁxed in 4% paraformaldehyde for 30 min and treated with
methanol and 0.1% Triton X-100 to achieve cell-membrane and nucle-
ar-membrane permeability. Non-speciﬁc binding was blocked by incu-
bation with normal swine serum (1:10; DAKO Co., Carpinteria, CA)
for 30 min. The chondrocytes were incubated overnight with 1:50 rab-
bit anti-human collagen I or II polyclonal antibody (Chemicon, Teme-
cula, CA) at 4 C, washed, incubated with 1:200 swine anti-rabbit
antibody (DAKO Co.) for 30 min at room temperature, again washed,
and incubated for 30 min with alkaline-phosphatase-labeled streptavi-
din (Vectastain ABC-AP; Vector, Burlingame, CA). Enzyme activity
of the alkaline phosphate complexes was assessed using 5-bromo-4-
chloro-3-indolyl phosphate/nitro blue tetrazolium chloride (BCIP/
NBT) color solution (Sigma–Aldrich, St. Louis, MO).blished by Elsevier B.V. All rights reserved.
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Chondrocytes seeded at 2 · 104 per well in 96-well culture plates
were cultured for 48 h and incubated for 24 h with diﬀerent doses of
AGE-BSA (MBL International, Woburn, MA). Cell viability was
measured using an XTT-based assay kit (Roche, Basel, Switzerland).
2.4. Zymography
For gelatin and casein zymography assays, equal volumes of condi-
tioned media and sample buﬀer (0.25 M Tris–HCl, 40% glycerol,
0.04% bromophenol blue, and 8% sodium dodecyl sulfate [SDS] pH
6.8) were mixed and incubated for 30 min at 37 C. Protein samples
were subjected to electrophoresis in 10% polyacrylamide gels contain-
ing 0.5 mg/ml gelatin or casein. The gels were washed twice with 2.5%
Triton X-100, 50 mM Tris–HCl, pH 7.5 for 30 min and incubated for
18 h in a calcium buﬀer (50 mM Tris–HCl, 200 mM NaCl, 10 mM
CaCl2, 1% Triton X-100, and 1 lM ZnCl2, pH 7.5). Gels were stained
with 0.05% Coomassie brilliant blue R-250 and destained with 10%
acetic acid until clear bands were observed against a dark background.
2.5. Western blot analysis
Protein concentrations were measured using the Bradford method.
Forty micrograms aliquots of protein were boiled in sample buﬀer
(0.5 M Tris–HCl, pH 6.8, 50% glycerol, 10% SDS, 0.5% bromophenol
blue, mercaptoethanol) for 4 min at 95 C, separated on 10% SDS–
PAGE (Bio-Rad, Hercules, CA), and transferred to nitrocellulose
membranes (Hybond-ECL; Amersham Biosciences, Freiberg,
Germany) using a Mini Trans-Blot (Bio-Rad). After blocking with
5% milk powder in phosphate-buﬀered saline (PBS) containing 0.5%
Tween 20 (Sigma–Aldrich) for 1 h, the membranes were incubated
overnight at 4 C with 1:200 rabbit anti-human anti-MMP-1, -3, or
-13 polyclonal antibodies (R&D Systems, Minneapolis, MN). The
membranes were washed with PBS containing 0.05% Tween 20 and
incubated with an alkaline-phosphatase-conjugated antibody (Chem-
icon) for 1 h. The immune complexes were visualized using BCIP/
NBT color solution (Sigma–Aldrich).
2.6. Enzyme-linked immunosorbent assay (ELISA)
The concentrations of MMP-1, -3, and -13, TNF-a and, interleukin
(IL)-1b in conditioned media were determined using commercially
available ELISA kits (R&D Systems) according to the manufacturer’s
instructions. Four ELISA experiments were conducted, with each sam-
ple tested in duplicate. The absorbance of the samples was measured
using a microplate spectrophotometer. Concentrations were obtained
from standard curves.
2.7. Electrophoretic mobility shift assay (EMSA)
Activation of the transcription factor NF-jB was assessed by EMSA
with consensus oligonucleotides of NF-jB (AGT TGA GGG GAC
TTT CCC AGG C; Promega, Madison, WI). Probes were end-labeled
with [c-32P] ATP (Amersham Biosciences) using T4 polynucleotide ki-
nase (Promega), and the labeled probes were puriﬁed on nick columns
(Amersham Biosciences). Following incubation of nuclear proteins
(5 lg) with labeled probes for 20 min at room temperature, the samples
were separated by 6% SDS–PAGE, and the gels was dried and sub-
jected to autoradiography. Supershift assays were also performed by
incubating nuclear extracts with polyclonal antibodies to the NF-jB
proteins p65 and p50 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) for 1 h at 4 C prior to the addition of the labeled probes.
2.8. Statistical analysis
Statistical analysis was performed using SPSS 11.0 software (SPSS,
Chicago, IL). The Mann–Whitney U test was used to compare pairs
of groups. The accepted level of signiﬁcance was P < 0.05. Data are
presented as means ± standard deviation (S.D.).Fig. 1. (A) Eﬀect of AGE-BSA on MMP activities in OA chondro-
cytes. Zymographic results (upper panel), and Western blotting results
(lower panel). (B) ELISA of expression of MMP-1, -3, and -13 (upper
panel), and TNF-a (lower panel). Results are representative of
duplicate experiments with OA chondrocytes obtained from six
donors. *P < 0.05.3. Results
3.1. Phenotype of OA chondrocytes
The cultured primary OA chondrocytes undergo marked
morphological changes with sequential passaging. OA chon-
drocytes dediﬀerentiate to a ﬁbroblast-like state when culturedin monolayer [13]. To examine the phenotypic characteristics
of the chondrocytes in this study, the OA chondrocytes were
stained with anti-collagen type I or type II 7 days after isola-
tion. Spherical or polygonal cells containing a single eccentric
nucleus were observed. Type II collagen was detected, but type
I collagen was not. Only OA chondrocytes with no evidence of
dediﬀerentiation that were grown within 5 days of isolation
were used.
3.2. Eﬀect of AGA-BSA on OA chondrocyte viability
To test whether AGE-BSA aﬀects the viability of OA chon-
drocytes, OA chondrocytes were treated with various doses of
AGE-BSA (0, 100, 200, 400, or 600 lg/ml) and then incubated
1930 S.-S. Nah et al. / FEBS Letters 581 (2007) 1928–1932for 24 h. Increasing doses of AGE-BSA had no signiﬁcant
cytotoxic eﬀects on OA chondrocytes.
3.3. Induction of MMP-1, -3, and -13, and TNF-a production by
AGE-BSA in OA chondrocytes
OA chondrocytes were treated with AGE-BSA (0, 100, 200,
400, or 600 lg/ml), and the expression of MMP-1, -3, and -13
was determined by zymography (Fig. 1A, upper panel). Using
casein gels, we found AGE-BSA dose-dependently induced
MMP activity, of molecular weights 40–60 kDa. Using gelatin
gels, however, we observed no MMP gelatinase activities, indi-
cating that MMP-2 and -9 are not stimulated by AGE-BSA
(data not shown). Since speciﬁc MMP subtypes could not be
identiﬁed by zymography, we used Western blot analysis to as-
say the expression levels of MMP-1, -3, and -13, all of which
have molecular weights of about 40–60 kDa in the AGE-
BSA-stimulated media (Fig. 1A, lower panel). We found
AGE-BSA signiﬁcantly and dose-dependently upregulated
the expression of MMP-1 and -3. The concentration of
MMP-13 in the media was too low to be determined by Wes-
tern blot analysis.
To conﬁrm that AGE-BSA-stimulated MMP expression, we
incubated OA chondrocytes with BSA (100, 200, 400 and
600 lg/ml) or AGE-BSA (100, 200, 400 and 600 lg/ml). Re-
sults were represented as fold changes of MMP-1, -3, or -13
productions by AGE-BSA compared with those by corre-
sponding dose of BSA. Treatment of OA chondrocytes withFig. 2. Eﬀects of AGE-BSA on (A) phosphorylation of JNK, p38,
and ERK and (B) NF-jB activity in OA chondrocytes. Results are
representative of samples obtained from four diﬀerent donors.
Fig. 3. Pharmacologic evaluations of AGE-BSA-induced production of M
representative of duplicate experiments with OA chondrocytes obtained fromincreasing dose of AGE-BSA resulted in signiﬁcant increases
in MMP-1, -3, and -13 protein levels in culture media in a
dose-dependent manner (Fig. 1B). We also assayed the concen-
trations of TNF-a and IL-1b in AGE-BSA-treated culture
media and observed AGE-BSA-stimulated TNF-a secretion
(P < 0.001), whereas BSA alone had no eﬀect (Fig. 1B).
AGE-BSA, however, had no eﬀect on IL-1b secretion (data
not shown).
3.4. Evaluation of the signaling pathway involved in AGE-BSA-
induced MMP-1, -3, and -13 and TNF-a expression
Western blot analyses showed that 400 lg/ml AGE-BSA
stimulated the phosphorylation of JNK, p38, and ERK
MAPKs (Fig. 2A). JNK phosphorylation started to increase
after 10 min, reached a maximum after 30 min, and decreased
1 h after AGE-BSA treatment. Similar results were observed
with p38 MAPK phosphorylation. Activation of ERK, how-
ever, reached a maximum level after 10 min and then de-
creased. We also observed that AGE-BSA increased NF-jB
activity in a dose-dependent manner and that p50 and p65
were super-shifted by 400 lg/ml AGE-BSA (Fig. 2B).
To investigate the signaling pathways involved in AGE-
BSA-induced expression of MMP-1, -3, and -13 and TNF-a
in OA chondrocytes, we utilized speciﬁc inhibitors of ERK
(PD98059), JNK (SP600125), p38 (SB202190), and NF-jB
(SN50). We found that both SP600125 and SB202190 signiﬁ-
cantly inhibited AGE-BSA-stimulated production of MMP-
1, -3, and -13, whereas PD98059 and SN50 did not (Fig. 3).
SP600125, SB202190 and SN50 markedly inhibited AGE-
BSA-stimulated production of TNF-a. Taken together, these
results suggest that JNK and p38 are involved in AGE-BSA-
stimulated expression of MMPs and TNF-a, whereas NF-jB
is involved only in AGE-BSA-activated TNF-a expression.
3.5. Evaluation of the engagement of RAGE
To determine the AGE receptors involved in AGE-BSA-in-
duced expression of MMP-1, -3, and -13, and TNF-a, OA
chondrocytes were pretreated with soluble receptor for AGE
(sRAGE) for 1 h before the addition of AGE-BSA (400 lg/
ml). We found that sRAGE signiﬁcantly reduced the expres-
sion levels of MMP-1 (41.3 ± 1.16%), -3 (21.8 ± 0.76%), and
-13 (41.2 ± 0.97%), and TNF-a (12.6 ± 0.83%) (P < 0.05,
Fig. 4). These results indicate that the stimulatory eﬀects of
AGE-BSA are partially RAGE-mediated.MP-1, -3, and -13 and TNF-a in OA chondrocytes. Results are
six donors. *P < 0.05.
Fig. 4. Evaluation of the engagement of RAGE in AGE-BSA-induced
production of MMP-1, -3, and -13 and TNF-a. Results are represen-
tative of duplicate experiments with OA chondrocytes obtained from
six donors. *P < 0.05.
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Previous studies have used complex AGE generated from
fatty-acid-free BSA or a speciﬁc AGE, usually pentosidine or
N3-carboxymethyllysine (CML). In contrast, we used com-
mercially available AGE-BSA, a complex that includes
CML, pentosidine, and other AGE, produced by reacting
BSA with glycolaldehyde under sterile conditions, followed
by extensive dialysis and puriﬁcation [14].
The activation of RAGE stimulates critical signaling path-
ways linked to proinﬂammatory, resulting in activation of var-
ious inﬂammatory genes [15]. The interaction of MAPKs and
RAGE has been reported [16–18]. Furthermore, rho-GTPases,
phosphoinositol-3-kinase, and the Janus kinase/signal trans-
ducer and activator of transcription (JAK/STAT) pathway
have been implicated in RAGE signaling [19–21]. Many of
these signaling cascades have been shown to result in activa-
tion of the downstream eﬀector NF-jB [15].
There are few reports on the interactions between AGE sig-
naling pathways and MAPKs in OA chondrocytes, and there
is little evidence that can be used to unravel the mechanisms
underlying the catabolic stimulatory eﬀects of AGE in articu-
lar chondrocytes. We have shown here that AGE-BSA-stimu-
lated production of MMP-1, -3, and -13 is mediated by the
JNK and p38-MAPK pathways. Although the phosphoryla-
tion levels of JNK, p38, and ERK were all increased by
AGE-BSA treatment, only SP600125 and SB202190 signiﬁ-
cantly inhibited the AGE-BSA stimulation of MMP-1, -3,
and -13 expression, indicating that JNK and p38 MAPKs
are directly involved. NF-jB is a transcription factor that is
known to be involved in AGE-mediated eﬀects. Although
NF-jB DNA binding activities were markedly increased by
AGE-BSA, pretreatment with SN50 did not signiﬁcantly inhi-
bit the production of MMP-1, -3, and -13, indicating that NF-
jB is not involved in this process.
Our results indicate that the mechanism by which AGE-BSA
induces TNF-a production diﬀers from that involved in MMP-
1, -3, and -13 stimulation. In addition to SP600125 and
SB202190, SN50 signiﬁcantly inhibited AGE-BSA-induced
TNF-a production in OA chondrocytes. These data indicate
that NF-jB may have a major role in TNF-a production by
OA chondrocytes, and that JNK and p38 may act upstream
of NF-jB.
The mechanisms underlying the eﬀects of AGE involve spe-
ciﬁc receptor-mediated signaling pathways. Glycated albumin-stimulated MMP-1 expression was blocked by a neutralizing
antibody against RAGE, the most characterized AGE recep-
tor, in OA ﬁbroblast-like synoviocytes [15], and sRAGE has
been shown to inhibit the increases in MMP-13 expression in-
duced by S100B, HMGB-1, or RAGE ligands [11,12]. Indeed,
we found that sRAGE inhibited MMP-1, -3, and -13, and,
TNF-a production, by OA chondrocytes. These ﬁndings indi-
cate that RAGE may mediate the eﬀects of AGE. However, we
cannot exclude the involvement of receptors other than RAGE
since the inhibitory eﬀect of RAGE is partial.Acknowledgement: This work was supported by the grant from Asan
Institute for Life Science (2004-330).References
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